Unlock instant, AI-driven research and patent intelligence for your innovation.
Frovatriptan succinate crystal and its pharmaceutical composition and use
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A kind of technology of frotriptan succinate and composition, applied in the field of frotriptan succinate crystal and pharmaceutical composition thereof
Inactive Publication Date: 2016-07-27
DIHON PHARMA GROUP
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] The commercial form of frovatriptan is frovatriptan succinate, and no crystal form has been reported so far
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0025] Add 1.00 g of frovatriptan succinate, 7.5 ml of ethanol, and 2.5 ml of water into a three-necked flask. Heat and stir in an oil bath at 80±2°C. When the solids are completely dissolved, stop heating, filter while hot, and slowly stir the filtrate. After cooling and crystallization, filtration, the filter cake was vacuum dried at 55±5°C for 6 hours to obtain 0.83 g of crystalline powder. Determine the powder X-raydiffraction pattern and data, infraredspectrogram, thermogravimetric analysis pattern and differential scanning pattern, according to the powder X-raydiffraction pattern (see figure 1 ) The characteristic absorption peak 2θ value 7.922, 8.339, 11.179, 15.837, 16.686, 17.525, 18.850, 21.265, 23.662, 24.905, 25.990 and 35.116cm -1 ), infraredspectrogram (see figure 2 , 3399.0, 3183.6, 3064.3, 2935.8, 2841.8,, 1665.7, 1628.0, 1585.5, 1567.9, 1479.5, 1262.0, 888.8, 812.8cm -1 ), thermogravimetric analysis chart (see image 3 ) And differential scanning calorimetr...
Embodiment 2
[0027] Add 1.00g of frovatriptan succinate, 9ml of ethanol, and 3ml of water into a three-necked flask. Heat and stir in an oil bath at 80±2℃. When the solid is completely dissolved, stop heating, filter while it is hot, and slowly cool the filtrate while stirring. Crystallized, filtered, and the filter cake was vacuum dried at 55±5°C for 6 hours to obtain 0.70 g of crystalline powder.
Embodiment 3
[0029] Add 1.00g of frovatriptan succinate, 6ml of ethanol and 2ml of water into a three-necked flask, heat and stir in an oil bath at 80±2℃ until the solids are dissolved, stop heating, filter while hot, and slowly cool the filtrate to crystallize while stirring. After filtering, the filter cake was vacuum dried at 55±5°C for 6 hours to obtain 0.67 g of crystalline powder.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a frovatriptan succinate crystal. The frovatriptan succinate crystal has characteristic absorption peaks at reflection angles 2 theta of 7.922, 8.339, 11.179, 15.837, 16.686, 17.525, 18.850, 21.265, 23.662, 24.078, 24.905, 25.155, 25.990 and 35.116cm<-1> in a X-ray power diffraction (XRPD) graph. The invention also relates to a pharmaceutical composition for treating migraine. The pharmaceutical composition contains the frovatriptan succinate crystals and one or more medicinal excipients. The invention also relates to a use of the frovatriptan succinate crystal in preparation of a drug for treating migraine.
Description
Technical field [0001] The invention belongs to the technical field of medicinal chemistry, and specifically relates to a frovatriptan succinate crystal and a pharmaceutical composition and application thereof. technical background [0002] Frotriptan is a second-generation triptan drug, a selective 5HT 1B And 5HT 1D Receptor subtype agonist, and 5HT 1B And 5HT 1D The receptor has a high affinity for 5HT 1B Its affinity is the strongest among the triptan drugs, and its mechanism of action is mainly to treat migraine by inhibiting the excessive expansion of the extracerebral and intracranial arteries. [0003] Frotriptan was first developed by GlaxoSmithKine and then transferred to Venalis. It was first listed in the United States in June 2002 under the trade name FROVA (EndoPharmaceuticals acquired the agency rights of this product in the United States). It is clinically used in adults with or without aura The acute treatment of migraine attacks is now available in many European co...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More